Latest Headlines

Latest Headlines

Philips to launch pneumonia Dx wearable to prevent child deaths in poorer countries

Almost one million childhood deaths are attributed to pneumonia annually, leading UNICEF to issue a call in 2011 for product innovation to create a respiratory monitor. Now, Royal Philips is almost ready to launch its Children's Automated Respiration Monitor that is designed to address those needs.

Israeli nitric oxide drug-device player files for up to $36M Nasdaq IPO

Rehovot, Israel-based Advanced Inhalation Therapies (AIT) has thrown its hat in the ring to raise up to $36.2 million in an IPO on the Nasdaq Exchange. That's despite the recent rocky market and a dearth of med tech IPOs of late.

Liverpool scientists point to a new heart therapy for deadly pneumonia toxin

Last fall Texas investigators demonstrated how infections triggered by Streptococcus pneumoniae could damage the heart, explaining why older adults hospitalized for pneumonia were at a high risk for often lethal complications. Now Liverpool researchers say the likely culprit--the toxin pneumolysin--can be neutralized by engineered fat bodies called liposomes.

Investigators advance a new therapy to use against pneumonia, influenza

Scientists say they've completed a successful mouse study of a new antibody designed to spur the recovery of patients suffering from pneumonia and influenza. And they're now preparing for human studies.

Sanofi inks a Korean alliance to develop a pneumococcal vaccine

The French Big Pharma is paying SK Chemicals $23 million up front, after which both companies will invest in the project.

Analysts offer mixed reactions to Pfizer's Prevnar 13 data close-up

Last month Pfizer presented positive headline results from its massive Prevnar 13 trial, but the release was light on the details that could shape whether the data leads to an expanded recommendation. Now Pfizer has published a closer look at the data, and not everyone likes what they see.

Genocea begins a PhI trial of its rival to Pfizer's Prevnar

The huge sales generated by Prevnar 13 mean Pfizer appears to have the pneumococcal vaccine sector sewn up, but Genocea Biosciences sees an opportunity to disrupt the monopoly. This week, the biotech began a Phase I clinical trial of the vaccine it thinks can unseat Prevnar.

Pfizer's Prevnar drives big fall in hospital visits

Prevnar pneumonia jabs have been wildly successful for Pfizer, racking up billions of dollars in sales and almost single-handedly driving its vaccine business.

Mass General repurposes cancer Dx tool for multiple use

Massachusetts General Hospital researchers repurposed a portable, fast-acting diagnostic device they developed to spot cancer as a successful test for tuberculosis and other infectious diseases such as pneumonia. Additionally, they used it to pinpoint antibiotic resistant bacteria such as the deadly MRSA.

Genocea wraps up $30M round for T-cell vaccines

Genocea Biosciences has raised $30 million in a Series C financing round to advance its T-cell vaccines for infectious diseases. With the close of this financing round, the clinical-stage company has landed a total of $76 million in equity financing to date.
  • 1
  • 2
  • 3
  • next ›
  • last »